Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Neogenomics Inc (NASDAQ: NEO) closed at $10.0 down -4.03% from its previous closing price of $10.42. In other words, the price has decreased by -$4.03 from its previous closing price. On the day, 1.73 million shares were traded. NEO stock price reached its highest trading level at $10.7335 during the session, while it also had its lowest trading level at $9.94.
Ratios:
For a deeper understanding of Neogenomics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 16 ’25 when ALICIA OLIVO bought 4,918 shares for $9.97 per share.
Sherman Jeffrey Scott bought 20,000 shares of NEO for $112,322 on Aug 06 ’25. The Chief Financial Officer now owns 188,332 shares after completing the transaction at $5.62 per share. On Aug 06 ’25, another insider, Zook Anthony P., who serves as the Chief Executive Officer of the company, bought 17,900 shares for $5.58 each. As a result, the insider paid 99,954 and bolstered with 38,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1293878016 and an Enterprise Value of 1540068992. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.82 while its Price-to-Book (P/B) ratio in mrq is 1.54. Its current Enterprise Value per Revenue stands at 2.172 whereas that against EBITDA is -447.304.
Stock Price History:
The Beta on a monthly basis for NEO is 1.61, which has changed by -0.34008867 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 9.24%, while the 200-Day Moving Average is calculated to be 14.79%.
Shares Statistics:
For the past three months, NEO has traded an average of 3.44M shares per day and 3056090 over the past ten days. A total of 128.89M shares are outstanding, with a floating share count of 125.25M. Insiders hold about 3.20% of the company’s shares, while institutions hold 95.69% stake in the company. Shares short for NEO as of 1761868800 were 7175657 with a Short Ratio of 2.08, compared to 1759190400 on 5926806. Therefore, it implies a Short% of Shares Outstanding of 7175657 and a Short% of Float of 7.64.
Earnings Estimates
The company has 13.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.02, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.12 and $0.08 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 13.0 analysts recommending between $0.3 and $0.06.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $188.4M this quarter.It ranges from a high estimate of $193M to a low estimate of $186.6M. As of. The current estimate, Neogenomics Inc’s year-ago sales were $172MFor the next quarter, 13 analysts are estimating revenue of $187.98M. There is a high estimate of $194.32M for the next quarter, whereas the lowest estimate is $183M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $730.2M, while the lowest revenue estimate was $721.8M, resulting in an average revenue estimate of $725.28M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $797.26M in the next fiscal year. The high estimate is $807.13M and the low estimate is $784.8M.
